TriSalus Life Sciences Exceeds 2025 Revenue Guidance, Projects Strong 2026 Growth

summarizeSummary

TriSalus Life Sciences announced preliminary unaudited financial results, reporting strong revenue growth for Q4 and full-year 2025 that exceeded prior guidance, and issued positive revenue guidance for 2026.

check_boxKey Events

• Exceeded 2025 Revenue Guidance

  Reported preliminary full-year 2025 revenue of approximately $45.2 million, representing 53% year-over-year growth, surpassing the company's 50% annual growth guidance.

• Strong Q4 2025 Revenue Growth

  Announced preliminary fourth quarter 2025 revenue of approximately $13.2 million, a 60% increase year-over-year and 14% sequential quarterly growth.

• Positive 2026 Revenue Guidance

  Set initial 2026 revenue guidance in the range of approximately $60 million to $62 million, indicating continued significant growth.

• Cash Position Update

  Estimated cash and cash equivalents of approximately $20.4 million as of December 31, 2025, reflecting a $2.3 million reduction during Q4 2025.

auto_awesomeAnalysis

The preliminary financial results indicate robust commercial performance, with full-year 2025 revenue surpassing the company's 50% growth target. The initial 2026 revenue guidance projects continued significant growth, reinforcing confidence in the company's strategic initiatives and product adoption. While cash and cash equivalents saw a modest reduction in Q4, the focus on operational efficiency alongside strong revenue growth suggests a manageable financial trajectory. Investors should monitor the final audited results and the company's progress towards its 2026 revenue targets.